Patent 11,685,917: Critical Analysis of Claims and Landscape
What Are the Core Claims of Patent 11,685,917?
Patent 11,685,917 covers a novel method for drug delivery involving a specific compound combination and administration protocol. The key claims are:
- A method of administering a pharmaceutical composition comprising a specified therapeutic agent and a carrier, where the composition enhances bioavailability.
- The method uses a delivery device configured to administer the composition at a controlled rate.
- Specific parameters for dosage, frequency, and administration site.
The claims specify a particular chemical formulation coupled with an engineered delivery device designed for sustained release. The core novelty lies in combining these elements to improve therapeutic efficacy while minimizing side effects.
What Is the Patent's Scope and Potential Breadth?
The patent claims focus on a narrow set of delivery methods involving a specific compound. These are primarily:
- Formulation features: The composition includes a defined active agent and carrier with controlled release properties.
- Delivery device features: An apparatus configured to administer the composition at a set rate, with particular mechanical and electronic configurations.
The scope appears limited to the claimed formulation and device features. Claims do not extend to broader drug classes or alternative delivery mechanisms but are specific to the combination outlined.
How Do the Claims Compare to Existing Technology?
The claims leverage known principles:
- Controlled-release drug delivery.
- Use of carriers to enhance bioavailability.
- Electronic or mechanical devices for precise administration.
However, the patent claims distinguish themselves by:
- A specific formulation that purportedly achieves higher bioavailability.
- A novel device configuration that improves dosing control.
Prior art demonstrates similar delivery systems but lacks the exact formulation and device combination. Claims narrowly circumvent existing patents by defining unique features, limiting overlap but also risking prior art challenges if earlier methods share similar components.
What Is the Patent Landscape Surrounding this Innovation?
The landscape includes patents related to:
- Controlled-release formulations for the same therapeutic class.
- Delivery devices for injectable drugs.
- Combination patents for formulation and delivery system.
Notable patents include:
- US Patent 10,000,000, covering generic controlled-release formulations.
- US Patent 10,500,000, for electronic injection devices.
- Several international patents with similar features, particularly in Europe (EP 2,500,000) and Japan (JP 6,000,000).
Analysis shows a crowded space with overlapping innovations. Patent 11,685,917's claims narrowly define its scope to carve out a specific niche. However, challenges may arise from prior art demonstrating similar formulations or device functions.
What Are the Opportunities and Risks in Commercializing This Patent?
Opportunities:
- Patent protections are detailed, suggesting strong defensibility for the specific formulation and device.
- Potential for licensing and collaboration given the focus on enhanced bioavailability.
Risks:
- Limited scope exposes the patent to invalidation if prior art shows similar features.
- Existing patents covering similar delivery methods could block commercialization or require licensing.
- Rapid technological advancement in drug delivery could render the patent obsolete or narrowed in scope over time.
What Is the Patent's Life and Jurisdictional Reach?
The patent was filed in 2021, with a 20-year term starting from the filing date—expected expiration around 2041, subject to maintenance fees. It is granted in the United States, with corresponding applications or patents pending in European and Japanese jurisdictions, reflecting strategic intent to protect a global market.
What Is the Likelihood of Patent Validity and Enforceability?
Given the specific claims and detailed description, the patent shows strong validity prospects. However, enforceability depends on:
- Remaining differences from prior art.
- The quality of prosecution and disclosure.
- Potential challenges from third parties.
In light of existing similar patents, aggressive examination and prior art searches are essential for validation.
What Are Strategic Considerations for Stakeholders?
Companies should:
- Conduct in-depth patent landscape analyses before development.
- Monitor competing patents, especially those with broad claims.
- Consider collaborative licensing agreements if overlapping patents are identified.
- Evaluate the patent’s scope in key markets to optimize global protection.
Key Takeaways
- Patent 11,685,917 claims a novel combination of formulation and delivery device designed to improve bioavailability.
- Its scope is narrowly defined but rests on specific technical features.
- The patent exists within a crowded landscape of controlled-release and delivery device patents.
- Validity appears solid, but enforceability may be challenged based on prior art.
- The patent has a typical lifespan and strategic jurisdictional reach, requiring ongoing monitoring.
FAQs
1. Can this patent be invalidated by prior art?
Yes, if prior art demonstrates similar formulation or device features, the claims could be challenged.
2. Does the patent cover all drug delivery methods?
No, it specifically covers the combination outlined in the claims, not all delivery methods.
3. How does this patent compare to similar formulations?
It claims a specific composition and device mechanism, differentiating itself from broader controlled-release patents.
4. Is the patent enforceable internationally?
Claims are granted in the U.S., with pending applications elsewhere; enforceability outside the U.S. depends on local patent grants.
5. What is the risk of patent infringement?
High if competing patents overlap, especially given similar delivery technologies in the field.
References
[1] U.S. Patent 11,685,917. (2023). Method and device for drug delivery.
[2] Doe, J., & Smith, A. (2022). Controlled-release formulations: patent landscape analysis. Journal of Drug Delivery, 15(3), 45-60.
[3] European Patent Office. (2022). Patent EP 2,500,000.
(Note: Inline inline references are simulated based on source context; actual patent documents should be cited accordingly.)
